Q1 EPS Estimate for BioLife Solutions Raised by Analyst

BioLife Solutions, Inc. (NASDAQ:BLFS) – Research analysts at HC Wainwright lifted their Q1 2025 earnings estimates for shares of BioLife Solutions in a research report issued on Wednesday, March 5th. HC Wainwright analyst Y. Chen now anticipates that the medical equipment provider will earn ($0.02) per share for the quarter, up from their previous estimate of ($0.10). HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for BioLife Solutions’ Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.16) EPS.

BioLife Solutions (NASDAQ:BLFS) last issued its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The company had revenue of $22.71 million for the quarter, compared to analysts’ expectations of $21.73 million. During the same quarter last year, the company posted ($0.21) earnings per share.

BLFS has been the subject of several other research reports. Benchmark reaffirmed a “buy” rating and set a $30.00 price target on shares of BioLife Solutions in a research report on Thursday, December 19th. Craig Hallum boosted their target price on shares of BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Northland Securities increased their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 8th. TD Cowen boosted their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Finally, KeyCorp raised their target price on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $29.86.

BioLife Solutions Stock Down 3.6 %

BioLife Solutions stock opened at $25.83 on Monday. BioLife Solutions has a one year low of $14.84 and a one year high of $29.55. The stock has a fifty day moving average of $26.65 and a 200 day moving average of $25.49. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The stock has a market cap of $1.21 billion, a PE ratio of -24.37 and a beta of 2.04.

Insider Activity at BioLife Solutions

In related news, EVP Aby J. Mathew sold 7,604 shares of BioLife Solutions stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $27.33, for a total transaction of $207,817.32. Following the sale, the executive vice president now owns 276,315 shares of the company’s stock, valued at approximately $7,551,688.95. This trade represents a 2.68 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Troy Wichterman sold 987 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $27.02, for a total value of $26,668.74. Following the completion of the transaction, the chief financial officer now owns 121,779 shares of the company’s stock, valued at $3,290,468.58. The trade was a 0.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 11,978 shares of company stock worth $322,724. 2.20% of the stock is owned by corporate insiders.

Institutional Trading of BioLife Solutions

Institutional investors and hedge funds have recently bought and sold shares of the stock. Principal Financial Group Inc. boosted its holdings in shares of BioLife Solutions by 4.7% during the 3rd quarter. Principal Financial Group Inc. now owns 190,715 shares of the medical equipment provider’s stock valued at $4,776,000 after purchasing an additional 8,580 shares during the last quarter. Summit Global Investments bought a new position in BioLife Solutions during the third quarter valued at approximately $228,000. Curi RMB Capital LLC boosted its stake in BioLife Solutions by 0.5% during the third quarter. Curi RMB Capital LLC now owns 421,933 shares of the medical equipment provider’s stock valued at $10,565,000 after buying an additional 2,283 shares during the last quarter. Quest Partners LLC purchased a new position in BioLife Solutions during the 3rd quarter valued at approximately $57,000. Finally, Intech Investment Management LLC bought a new stake in BioLife Solutions in the 3rd quarter worth approximately $255,000. 93.24% of the stock is currently owned by institutional investors.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.